Publications Repository

Publications Repository

View item 
  •   Home
  • ICR Divisions
  • Cancer Therapeutics
  • View item
  • Home
  • ICR Divisions
  • Cancer Therapeutics
  • View item
JavaScript is disabled for your browser. Some features of this site may not work without it.

Small-molecule targeting of brachyury transcription factor addiction in chordoma.

Thumbnail
View/Open
Accepted version (4.526Mb)
Date
2019-02
ICR Author
Clarke, Paul
Author
Sharifnia, T
Wawer, MJ
Chen, T
Huang, Q-Y
Weir, BA
Sizemore, A
Lawlor, MA
Goodale, A
Cowley, GS
Vazquez, F
Ott, CJ
Francis, JM
Sassi, S
Cogswell, P
Sheppard, HE
Zhang, T
Gray, NS
Clarke, PA
Blagg, J
Workman, P
Sommer, J
Hornicek, F
Root, DE
Hahn, WC
Bradner, JE
Wong, KK
Clemons, PA
Lin, CY
Kotz, JD
Schreiber, SL
Show allShow less
Type
Journal Article
Metadata
Show full item record
Abstract
Chordoma is a primary bone cancer with no approved therapy 1 . The identification of therapeutic targets in this disease has been challenging due to the infrequent occurrence of clinically actionable somatic mutations in chordoma tumors 2,3 . Here we describe the discovery of therapeutically targetable chordoma dependencies via genome-scale CRISPR-Cas9 screening and focused small-molecule sensitivity profiling. These systematic approaches reveal that the developmental transcription factor T (brachyury; TBXT) is the top selectively essential gene in chordoma, and that transcriptional cyclin-dependent kinase (CDK) inhibitors targeting CDK7/12/13 and CDK9 potently suppress chordoma cell proliferation. In other cancer types, transcriptional CDK inhibitors have been observed to downregulate highly expressed, enhancer-associated oncogenic transcription factors 4,5 . In chordoma, we find that T is associated with a 1.5-Mb region containing 'super-enhancers' and is the most highly expressed super-enhancer-associated transcription factor. Notably, transcriptional CDK inhibition leads to preferential and concentration-dependent downregulation of cellular brachyury protein levels in all models tested. In vivo, CDK7/12/13-inhibitor treatment substantially reduces tumor growth. Together, these data demonstrate small-molecule targeting of brachyury transcription factor addiction in chordoma, identify a mechanism of T gene regulation that underlies this therapeutic strategy, and provide a blueprint for applying systematic genetic and chemical screening approaches to discover vulnerabilities in genomically quiet cancers.
URI
https://repository.icr.ac.uk/handle/internal/3536
DOI
https://doi.org/10.1038/s41591-018-0312-3
Collections
  • Cancer Therapeutics
Subject
Humans
Chordoma
Cyclin-Dependent Kinases
T-Box Domain Proteins
Fetal Proteins
Transcription Factors
Protein Kinase Inhibitors
Cell Proliferation
Down-Regulation
Genes, Essential
Small Molecule Libraries
Research team
Signal Transduction & Molecular Pharmacology
Language
eng
Date accepted
2018-11-26
License start date
2019-02
Citation
Nature medicine, 2019, 25 (2), pp. 292 - 300

Browse

All of ICR repositoryICR DivisionsBy issue dateAuthorsTitlesPublication TypesThis collectionBy issue dateAuthorsTitlesPublication Types
  • Login
  • Registered office: The Institute of Cancer Research, 123 Old Brompton Road, London, SW7 3RP
    A Charity, Not for Profit. Company Limited by Guarantee.
    Registered in England No. 534147. VAT Registration No. GB 849 0581 02.